Ivosidenib
Brand name: Tibsovo
Rank #347 of 500 drugs by total cost
$28.9M
Total Cost
931
Total Claims
$28.9M
Total Cost
67
Prescribers
$31K
Cost per Claim
0
Beneficiaries
934
30-Day Fills
$431K
Avg Cost/Provider
14
Avg Claims/Provider
About Ivosidenib
Ivosidenib (sold as Tibsovo) was prescribed 931 times by 67 Medicare Part D providers in 2023, costing the program $28.9M. At $31K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 344 | Amiodarone Hcl (Amiodarone Hcl) | $29.9M | 1,007,679 |
| 345 | Esketamine Hcl (Spravato) | $29.0M | 20,816 |
| 346 | Warfarin Sodium (Warfarin Sodium) | $28.9M | 2,126,832 |
| 347 | Ivosidenib (Tibsovo) | $28.9M | 931 |
| 348 | Cyclobenzaprine Hcl (Cyclobenzaprine Hcl) | $28.7M | 2,582,519 |
| 349 | Atenolol (Atenolol) | $28.6M | 2,717,988 |
| 350 | Meloxicam (Meloxicam) | $28.6M | 4,714,084 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology